Drug intelligence / Profile preview

SCP-787

Development stage: Preclinical
Lead developer: Silver Creek Pharmaceuticals
Administration: Topical

Overview

SCP-787 is an investigational drug candidate initially developed by Silver Creek Pharmaceuticals. It is currently in preclinical development, with its primary therapeutic area being skin and cosmetic dermatology applications. Specific details about its mechanism of action, molecular target, or modality have not been disclosed publicly. The drug is part of Silver Creek Pharmaceuticals' pipeline focused on smart growth factors technology for improved pharmacodynamics and pharmacokinetics[1][5].

Beyond the preview

Go deeper on SCP-787.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SCP-787.

Explore the full profile